
Learn why sexual changes carry more weight than fatigue in testosterone assessments, and how clinicians use repeat blood tests and related biomarkers.

Sexual changes and nonspecific complaints carry different weight in a low testosterone assessment, shaping how clinicians weigh possible hormone deficiency against other explanations.
This article is for informational purposes and is not medical advice. Questions about personal symptoms, blood tests or treatment should be discussed with a qualified clinician.
The European Association of Urology (EAU) identifies sexual symptoms as the most specific symptoms associated with late-onset hypogonadism. Its guidance gives greater diagnostic weight to these changes than to complaints such as reduced energy or difficulty concentrating.
The sexual symptoms it highlights are:
Here, “more specific” means more informative within the assessment. It does not mean exclusive to testosterone deficiency or sufficient for diagnosis. The EAU states that these symptoms must be interpreted alongside the wider clinical picture and biochemical findings.
Reduced libido means reduced sexual desire. In the EAU framework, a change in desire is a relevant part of the symptom pattern rather than simply another item on a general wellness checklist.
A useful clinical description separates interest in sex from erection quality. A man may be concerned about desire, erections or both. Explaining which aspect has changed gives the clinician a clearer sexual history than saying only that sexual function feels different.
The duration and pattern of the change also belong in that discussion, according to the EAU’s approach to assessment.
The EAU includes decreased spontaneous or morning erections among the more specific sexual symptoms. This is a distinct observation from reduced desire and from difficulties with erections during sexual activity.
The useful detail is the change being described. A clinician can consider whether fewer morning erections occur alongside lower desire or changes in erection quality. Keeping these observations separate preserves information that can be lost under the broad phrase “sexual problems.”
Erectile dysfunction also belongs in the EAU’s more specific symptom group. However, its place in that group is only one part of its clinical importance.
The EAU’s separate ED guidance calls for a sexual history and a broader health assessment. That broader evaluation matters because erection difficulties can involve mechanisms beyond testosterone, as discussed below.
For more context on describing these changes, see how clinicians assess different aspects of sexual function.
Fatigue and sleep problems describe a different set of concerns from changes in desire or erections. The EAU’s symptom table also includes low mood and reduced motivation among complaints that may occur with hypogonadism but are not uniquely attributable to it.
Other less specific complaints in the guideline include:
The distinction is about diagnostic weight, not how disruptive a symptom feels. A complaint can deserve medical attention without strongly pointing toward testosterone deficiency. Calling fatigue “nonspecific” does not mean that it is unimportant or that it should be dismissed.
These complaints help describe the broader clinical picture. Sexual symptoms provide a more focused clue within the EAU framework, while energy and mood changes add information about the person’s overall concerns.
This is also why a long symptom list should not become a scoring system. The guideline’s approach combines the nature of the symptoms with laboratory evidence. It does not establish hypogonadism by counting how many general complaints someone reports.
For someone preparing for a consultation, the practical task is to describe each concern clearly. Grouping tiredness and reduced motivation together may be convenient, but explaining them separately helps preserve the symptom pattern being assessed.
The comparison is therefore not “sexual symptoms matter and fatigue does not.” It is that different symptoms contribute different kinds of information. Testostra’s discussion of why broad symptom checklists can mislead develops that distinction.
The EAU framework brings symptoms and laboratory findings into the same assessment. Sexual changes help focus the clinical questions. Nonspecific complaints help describe the wider picture, while blood testing supplies a separate form of evidence.
The assessment can bring together:
These elements serve different purposes. The symptom history describes what has changed. Laboratory testing establishes the hormone findings, while the health review helps clinicians consider possible explanations for both.
The EAU’s diagnostic framework requires compatible symptoms or signs together with low morning testosterone confirmed on at least two occasions. It specifies fasting conditions and a reliable assay, meaning the method used to measure testosterone.
The guideline recommends measuring testosterone between 07:00 and 10:00 and repeating a low result on separate occasions. These are clinical testing recommendations rather than a basis for arranging a self-directed diagnostic process.
The EAU also identifies 12 nmol/L as a reference threshold for diagnosing late-onset hypogonadism in the appropriate clinical context. The threshold belongs alongside the symptomatic profile and other findings. It is not an automatic treatment rule.
This approach gives the symptom comparison a clear purpose. More informative symptoms help clinicians assess the relevance of the hormone findings. Repeated measurements provide the biochemical evidence needed to move beyond an impression based on symptoms alone.
For further explanation of that relationship, read about combining symptoms with confirmed laboratory findings.
The EAU recommends reviewing accompanying diseases and any medicines or substances that may interfere with testosterone production or action. This places the hormone result within the person’s medical history rather than treating it as an isolated number.
Acute illness is a specific testing consideration. The guideline notes that it can be associated with functional hypogonadism and advises against measuring testosterone during acute disease.
For the clinical conversation, relevant context includes what was happening when symptoms developed and when testing occurred. The clinician can then decide how that history affects the interpretation and timing of further assessment.
The EAU says free testosterone assessment should be considered when sex hormone-binding globulin, or SHBG, may be altered. Its reason is that total testosterone can vary with SHBG levels.
This connects the symptom discussion with a common source of laboratory confusion. Total testosterone is part of the assessment, but the guideline identifies circumstances in which SHBG and free testosterone can add useful context.
The recommendation is conditional rather than a requirement for everyone to receive the same panel. Whether these measurements are useful depends on the existing results and the clinical situation.
For readers, the useful question is why a particular biomarker is being considered. That keeps attention on the clinical purpose of the measurement rather than on collecting more numbers.
When testosterone is low, the EAU recommends measuring luteinising hormone (LH) and follicle-stimulating hormone (FSH). These measurements help distinguish types of hypogonadism.
The guideline also recommends prolactin testing when reduced sexual desire or other suggestive signs occur with secondary hypogonadism. This is a targeted recommendation tied to the clinical findings, not a general instruction for every man with fatigue.
These biomarkers address a different question from the symptom history. Symptoms describe the concern that brought someone to care. Additional hormone measurements can help clinicians investigate the nature of a low testosterone finding.
The EAU describes erectile dysfunction as multifactorial. Its hypogonadism guidance identifies vascular disease and neuropathic disease as important mechanisms. It also notes that ED is common in men with metabolic syndrome and type 2 diabetes.
The EAU’s ED guidance therefore includes possible metabolic and cardiovascular risk factors in the evaluation. It recommends considering glucose or HbA1c and lipid testing when these have not been assessed recently. Early-morning testosterone is included in hormonal testing.
This broader assessment remains relevant when testosterone is normal or has not yet been measured. Erection difficulties warrant attention in their own right, rather than being treated only as a route to a testosterone diagnosis.
A practical discussion with a qualified clinician can cover the sexual changes themselves and the wider health history. Describing desire, spontaneous erections and erection quality separately gives that discussion a clear starting point without assigning the cause in advance.
Sexual symptoms offer more focused clues, while nonspecific complaints and contextual blood tests help clinicians assess the whole person rather than a symptom count.
Understanding the relationship between total testosterone and related biomarkers is a concrete educational goal that Testostra addresses through clear reporting. For men puzzled by free testosterone or SHBG, the publication connects hormone terminology with clinical context while keeping personal diagnosis and treatment outside its educational role.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra